|
Datopotamab Deruxtecan Late-Breaking Data at ESMO Breast Shows Promising Preliminary Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer
|
Oral presentation highlighting first results from TROPION-PanTumor01 in patients with triple negative breast cancer shows preliminary clinical activity TOKYO & MUNICH & BASKING RIDGE, N.J.--(BUSINESS WIRE)--New data from Daiichi Sankyo Company, Limi...
Full "IntellAsia: Resources" article
|
|